THE BEST WAY TO HTA? QUEBEC VERSUS THE REST OF CANADA

Author(s)

Macaulay R, Hugon M, Griffiths EA
PAREXEL, London, UK

OBJECTIVES: The Canadian Agency for Drugs and Technologies in Health (CADTH) makes reimbursement recommendations to provincial public drug plans to help guide drug funding decisions. The exception is Quebec, where the Institut National d’Excellence en Santé et en Services Sociaux (INESSS) conducts separate assessments. This research compares drug recommendations between CADTH and INESSS. METHODS: Publically available CADTH (including both Common Drug Review [CDR] and pan-Canadian Oncology Drug Review [pCODR] processes) and INESSS reports on drug assessments were identified between 01/31/2015 and 11/30/2016, and key data were extracted and compared. RESULTS:

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PHP33

Topic

Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Health Technology Assessment

Topic Subcategory

Approval & Labeling, Cost/Cost of Illness/Resource Use Studies, Decision & Deliberative Processes, Health Care Research, Health Disparities & Equity, Prescribing Behavior, Pricing Policy & Schemes, Reimbursement & Access Policy, Risk-sharing Approaches

Disease

Multiple Diseases

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×